Leanbio, member of CataloniaBio & HealthTech, adds 20 million euros of investment to its plant, currently on construction, in Sant Quirze del Vallès (Barcelona), which will become one of the most advanced in Europe. The company, based at the Barcelona Science Park, is expanding its production capacity in response to a growing demand for global projects, and has already secured licensing agreements for biosimilars with major multinational companies in the sector.
In their more than 3.500m², the infrastructure will receive three production lines with the capacity to manufacture both recombinant proteins and antibodies, in different expression systems, as well as plasmid DNA and messenger RNA for advanced therapies within the sector. It will also include development laboratories, scaling areas, pilot production plants and quality control.
With a high technological component in its processes and facilities incorporating state-of-the-art equipment, the plant becomes an European benchmark and represents a significant strategic advance for the Spanish state, facilitating access to the production of highly complex and essential pharmaceuticals. This facility is the first of its kind in the technological hub of Barcelona, contributing to the consolidation of the cluster as a hub for attracting talent, research, and biotechnological investment.
The initiative has been selected in the latest call for aid for strategic projects within the framework of the PERTE per a la Salut d’Avantguarda, which is part of the Recovery, Transformation and Resilience Plan financed by European funds. This instrument is aimed at promoting innovative technological projects in the pharmaceutical sector that must also meet strict sustainability criteria. This European recognition reaffirms Leanbio's values and its commitment to the development and manufacturing of drugs through sustainable processes.
Comments